Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial — Gerald G. Krueger (2005) | RDL Network
Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial
Article 2005 en
Authors
GK
Gerald G. Krueger
RL
Richard G. Langley
AF
A.Y. Finlay
Abstract
1 min read
Etanercept therapy improves PROs in patients with psoriasis and makes a meaningful difference to their lives. These results support the efficacy profile of physician-reported clinical measures while providing a more complete understanding of the benefits experienced by patients with psoriasis treated with etanercept.
William D. Tap, Vivek A. Bhadri, Silvia Stacchiotti, Sebastian Bauer, Andrew J. Wagner, Michiel A. J. van de Sande, Nicholas M. Bernthal, Antonio López–Pousa, Albiruni Ryan Abdul Razak, Antoîne Italiano, Mahbubl Ahmed, Axel Le Cesne, Christopher Tait, Fiona Zarins, B. Harrow, Maitreyi G. Sharma, Rodrigo Ruiz‐Soto, Matthew L. Sherman, Jean Yves Blay, Hans Gelderblom
H. Bachelez, Christopher Em Griffiths, Kim Papp, Stephen Hall, Joseph F. Merola, Steven R. Feldman, Majed Khraishi, Huaming Tan, Lara Fallon, Joseph C. Cappelleri, Andrew G. Bushmakin, Pamela Young
Alessandra Tedeschi, Meletios A Dimopoulos, Judith Trotman, Ramón García‐Sánz, David MacDonald, Beatrice Mahé, Charles Herbaux, Leonard T. Heffner, Constantine S. Tam, Marzia Varettoni, Maria Lia Palomba, Jeffrey Matous, Chaim Shustik, Efstathios Kastritis, Steven P. Treon, Jianling Li, Erik Poulsen, Bernhard Hauns, Christian Buske, Véronique Leblond
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.